Familial Hypercholesterolemia - Homozygous
Metabolic·MeSH: Hypercholesterolemia
Prevalence
0.5 / 100K
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| inclisiran sodium 300 mg in | Novartis AG (NVS) |
Frequently asked questions
How many drugs are in development for Familial Hypercholesterolemia - Homozygous?
BioSniper tracks 1 drug in development for Familial Hypercholesterolemia - Homozygous across 1 company.
How many clinical trials target Familial Hypercholesterolemia - Homozygous?
There are 1 clinical trial targeting Familial Hypercholesterolemia - Homozygous tracked by BioSniper.
What is the prevalence of Familial Hypercholesterolemia - Homozygous?
The estimated prevalence of Familial Hypercholesterolemia - Homozygous is approximately 0.5 per 100,000 population.
Deep-dive into Familial Hypercholesterolemia - Homozygous
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis